Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2009 1
2010 1
2011 2
2013 2
2014 5
2015 6
2016 1
2017 4
2018 3
2019 4
2020 10
2021 9
2022 9
2023 15
2024 3
2025 10
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

79 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
Maurer M, Ensina LF, Gimenez-Arnau AM, Sussman G, Hide M, Saini S, Grattan C, Fomina D, Rigopoulos D, Berard F, Canonica GW, Rockmann H, Irani C, Szepietowski JC, Leflein J, Bernstein JA, Peter JG, Kulthanan K, Godse K, Ardusso L, Ukhanova O, Staubach P, Sinclair R, Gogate S, Thomsen SF, Tanus T, Ye YM, Burciu A, Barve A, Modi D, Scosyrev E, Hua E, Letzelter K, Varanasi V, Patekar M, Severin T; PEARL-1 and PEARL-2 trial investigators. Maurer M, et al. Lancet. 2024 Jan 13;403(10422):147-159. doi: 10.1016/S0140-6736(23)01684-7. Epub 2023 Nov 23. Lancet. 2024. PMID: 38008109 Clinical Trial.
Management of Atopy with Dupilumab and Omalizumab in CADINS Disease.
Diaz-Cabrera NM, Bauman BM, Iro MA, Dabbah-Krancher G, Molho-Pessach V, Zlotogorski A, Shamriz O, Dinur-Schejter Y, Sharon TD, Stepensky P, Tal Y, Eisenstein EM, Pietzsch L, Schuetz C, Abreu D, Coughlin CC, Cooper MA, Milner JD, Williams A, Armoni-Weiss G, Snow AL, Leiding JW. Diaz-Cabrera NM, et al. Among authors: tal y. J Clin Immunol. 2024 Jan 17;44(2):48. doi: 10.1007/s10875-023-01636-y. J Clin Immunol. 2024. PMID: 38231347
Severe eosinophilia in hospitalized patients.
Tal Y, Hershcovich I, Talmon A, Ribak Y, Shamriz O, Toker O, Hershko AY. Tal Y, et al. J Intern Med. 2022 Mar;291(3):377-379. doi: 10.1111/joim.13407. Epub 2021 Nov 11. J Intern Med. 2022. PMID: 34700358 Free article. No abstract available.
Dupilumab for cancer-associated refractory pruritus.
Talmon A, Elias S, Rubin L, Ribak Y, Ben Dori E, Shamriz O, Lotem M, Adini I, Tal Y. Talmon A, et al. Among authors: tal y. J Allergy Clin Immunol Glob. 2023 Jun 23;2(3):100128. doi: 10.1016/j.jacig.2023.100128. eCollection 2023 Aug. J Allergy Clin Immunol Glob. 2023. PMID: 37779518 Free PMC article.
β-Actin Deficiency in Baraitser-Winter Syndrome Type 1 Disrupts T-Cell Function and Immune Regulation: Implications for Targeted Therapy in Actinopathies.
Bar-On Z, Reuven O, Lev A, Simon AJ, Salaymeh W, Shalom A, Somech R, Barel O, Porges S, Javasky E, Molho-Pessach V, Granot Z, Bijaoui D, Neuman T, Tal Y, Baniyash M, Berger M, Shamriz O. Bar-On Z, et al. Among authors: tal y. J Clin Immunol. 2025 Aug 1;45(1):120. doi: 10.1007/s10875-025-01906-x. J Clin Immunol. 2025. PMID: 40748410 Free PMC article.
79 results